Tumor Models Boston Summit 2024

Lab-in-the-loop: Leveraging Tumor Organoids and RWD to Generate Multimodal Insights for Drug Development

High failure rates and increased costs in drug development are driven by lack of robust preclinical models in the discovery and translational space. Tempus has built a platform of 3D patient-derived organoids (PDOs) grounded in de-identified real-world clinical data to address this gap. With one of the largest, pan-indication patient-derived organoid repositories in the industry, Tempus' portfolio of fixed screening panels supports research questions across a range of modalities including small molecules, antibody drug conjugates, and cell therapies.